PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.35 (+0.03), ISIS: 59.49 (+1.88), DRNA: 16.23 (-0.23), ALNY: 93.52 (+0.97), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), ALXN: 181.96 (+3.09), TKMR: 13.97 (+0.14), RGLS: 14.78 (+0.24)
Rosetta Genomics to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on December 3, 2014
Business Wire - Tue Nov 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ROSG: 2.35 (+0.03)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 2.35 (+0.03), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 2.35 (+0.03)
Rosetta Genomics Announces Publication of Data Demonstrating Differentiation of Adrenocortical Carcinomas from Adenomas by microRNA Profiling
Business Wire - Tue Nov 04, 7:38AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of data relating to the Company's microRNA platform in the online edition of peer-reviewed journal, "Applied Immunohistochemistry and Molecular Morphology." The article entitled, "Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate with Weiss Histopathologic System," highlights the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas with very good correlation with the histologic Weiss system for identifying malignancy in adrenocortical tumors (ACTs). This study is part of a collaborative project between Rosetta Genomics and Prof. Meora Feinmesser, M.D., Head of the Institute of Pathology at the Rabin Medical Center in Israel.
ROSG: 2.35 (+0.03)
Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests
Business Wire - Thu Oct 30, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
ROSG: 2.35 (+0.03)
Rosetta Genomics' microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th Annual Meeting of the American Thyroid Association
Business Wire - Thu Oct 23, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in support of the Company's microRNA-based assay for indeterminate thyroid nodules will be highlighted in a poster presentation entitled, "MicroRNAs as a powerful diagnostic tool for thyroid nodule classification in pre-operative samples," at the upcoming 84th Annual Meeting of the American Thyroid Association (ATA) taking place from October 29th through November 2nd at the Hotel Del Coronado in Coronado, Calif.
ROSG: 2.35 (+0.03)
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic
Marketwired - Tue Oct 21, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool.
ROSG: 2.35 (+0.03)
Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 2.35 (+0.03), BIOC: 2.48 (-0.04)
ROSG, BCOM, ENTR, HEES, LOV, ARI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 24, 3:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Rosetta Genomics Ltd (NASDAQ:ROSG), B Communications Ltd (NASDAQ:BCOM), Entropic Communications Inc (NASDAQ:ENTR), H&E Equipment Services Inc (NASDAQ:HEES), Spark Networks Inc (NYSE:LOV), Apollo Commercial Real Estate Finance Inc (NYSE:ARI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 2.35 (+0.03), BCOM: 18.18 (-0.64), ARI: 16.86 (-0.04), HEES: 28.38 (-0.59), LOV: 3.75 (-0.05), ENTR: 2.26 (-0.06)
Market Maker Surveillance Report. NYNY, MOBI, EPIQ, YRCW, ROSG, HPJ, Winning Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Empire Resorts Inc (NASDAQ:NYNY), Sky-mobi Ltd (NASDAQ:MOBI), Epiq Systems Inc (NASDAQ:EPIQ), YRC Worldwide Inc (NASDAQ:YRCW), Rosetta Genomics Ltd (NASDAQ:ROSG), Highpower International Inc (NASDAQ:HPJ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ROSG: 2.35 (+0.03), HPJ: 5.03 (+0.14), EPIQ: 16.99 (-0.22), MOBI: 4.09 (+0.21), NYNY: 7.89 (+0.32), YRCW: 23.52 (-0.15)
Rosetta Genomics Reports Financial Results for the First Half of 2014
eTeligis - Wed Sep 17, 6:56PM CDT
PRINCETON, NJ, United States, via ETELIGIS INC., 09/17/2014 - - Business Update Conference Call to Be Held September 18th at 10:00 a.m. Eastern Time
ROSG: 2.35 (+0.03)
Rosetta Genomics to Host Business Update Conference Call on September 18, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Wednesday, September 17, 2014, the Company will file financial results for the six months ended June 30, 2014 on Form 6-K with the U.S. Securities and Exchange Commission ("SEC"
ROSG: 2.35 (+0.03)
Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test
Marketwire - Wed Sep 03, 7:19AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the initiation of the Rosetta Cancer Origin Test(TM) Patient Registry study (COPR), a two-part global registry attempting to evaluate the impact of the Cancer Origin Test on treatment decisions in patients diagnosed with metastatic cancers or Cancers of Unknown or Uncertain Primary (CUP). COPR will also attempt to track treatments selected, duration of response to therapies, survival and other clinically relevant information including additional diagnostic testing performed.
ROSG: 2.35 (+0.03)